EUVIMEDEUVIMED entdecken
Open Access

KRAS is required for plexiform neurofibroma formation and represents a targetable vulnerability in established tumors

Liang Hu iD, Niousha Ahmari, Abby Schaeper iD, Jay Pundavela iD, Mi-Ok Kim iD, Eva Dombi iD, Jianqiang Wu iD, Julia Brunmair iD, Özlem Yüce Petronczki, Nancy Ratner iD

Science Advances · 04.09.2026 · 12 (36)

DOI: 10.1126/sciadv.aeg3475 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 04.09.2026. Verfasst von Liang Hu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, 3333 Burn…. Hauptthemen laut MEDLINE: Neurofibroma, Plexiform, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NICHD NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with neurofibromatosis type 1 develop Schwann cell tumors called neurofibromas that arise within peripheral nerves, driven by loss of neurofibromin and consequent increased RAS/RAF/MEK signaling. MEK inhibitors achieve partial responses for benign neurofibromas but are limited by toxicity and incomplete efficacy, necessitating alternative approaches. Using the Dhh- Cre; Nf1 fl/fl neurofibroma mouse model, we found that genetic ablation of Kras , but not Hras , markedly reduced neurofibroma development, inhibited MAPK activation, and rescued disrupted Remak bundles that are a morphologic hallmark of neurofibromas. These findings reveal a RAS paralog–specific requirement for KRAS in NF1-deficient neurofibroma initiation. Pharmacological KRAS inhibition with BI6674, an orally bioavailable KRAS multi inhibitor, reduced tumor volume and proliferation in established neurofibromas and remodeled the tumor immune microenvironment, decreasing macrophages and dendritic cells. Combining KRAS and MEK inhibition further enhanced tumor regression. These findings demonstrate that KRAS is essential for neurofibroma formation and represents a promising therapeutic target, supporting clinical evaluation of KRAS inhibition for neurofibromas in patients with neurofibromatosis type 1.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neurofibroma, PlexiformProto-Oncogene Proteins p21(ras)AnimalsMiceDisease Models, AnimalNeurofibromatosis 1Tumor MicroenvironmentHumansNeurofibromin 1Cell Proliferation

Substanzen

Proto-Oncogene Proteins p21(ras)Neurofibromin 1Hras protein, mouse

Autor:innen und Institutionen

  • Division of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, USA.
  • Department of Epidemiology and Biostatistics, UCSF, 1450 3rd Street, San Francisco, CA 94143, USA.
  • Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA.
  • Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
  • Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer Gasse 5-11, A-1120 Vienna, Austria.

ORCID-Profile: Liang Hu, Abby Schaeper, Jay Pundavela, Mi-Ok Kim, Eva Dombi, Jianqiang Wu, Julia Brunmair, Nancy Ratner

Förderung

  • NINDS NIH HHS
  • NICHD NIH HHS
  • National Institutes of Health
  • National Institute of Neurological Disorders and Stroke
  • Boehringer Ingelheim Inc
  • Strauss Fellowship

Zitieren

APA

Hu, L., Ahmari, N., Schaeper, A., Pundavela, J., Kim, M. O., Dombi, E., Wu, J., Brunmair, J., Petronczki, Ö. Y., & Ratner, N. (2026). KRAS is required for plexiform neurofibroma formation and represents a targetable vulnerability in established tumors. Science Advances, 12(36). https://doi.org/10.1126/sciadv.aeg3475

Vancouver

Hu L, Ahmari N, Schaeper A, Pundavela J, Kim MO, Dombi E, et al. KRAS is required for plexiform neurofibroma formation and represents a targetable vulnerability in established tumors. Science Advances. 2026;12(36). doi:10.1126/sciadv.aeg3475

BibTeX
@article{Hu2026,
  author = {Hu, Liang and Ahmari, Niousha and Schaeper, Abby and Pundavela, Jay and Kim, Mi-Ok and Dombi, Eva and Wu, Jianqiang and Brunmair, Julia and Petronczki, Özlem Yüce and Ratner, Nancy},
  title = {KRAS is required for plexiform neurofibroma formation and represents a targetable vulnerability in established tumors},
  journal = {Science Advances},
  year = {2026},
  volume = {12},
  number = {36},
  doi = {10.1126/sciadv.aeg3475}
}
Kostenlos starten →